Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts $244.89 -1.91 (-0.77%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Alnylam Pharmaceuticals Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 20EstimatedActual EPS (Oct. 31) -$0.87 Missed By -$0.36 Consensus EPS (Oct. 31) -$0.51 Alnylam Pharmaceuticals released Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.87, which missed analysts' consensus estimates of -$0.51 by $0.36. Quarterly revenue fell 33.3% year-over-year to $500.90 million, below analysts' expectations of $532.91 million. With a trailing EPS of -$2.62, Alnylam Pharmaceuticals' earnings are expected to grow next year, from ($2.22) to ($1.88) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingALNY Upcoming EarningsAlnylam Pharmaceuticals' next earnings date is estimated for Thursday, February 20, 2025, based off prior year's reporting schedules. Get Alnylam Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alnylam Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALNY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALNY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...Not everything is as rosy as it seems on Wall Street. Alnylam Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.26-$0.70-$1.02Q2 20244-$1.38-$0.90-$1.13Q3 20244-$1.12-$0.91-$1.02Q4 20244-$1.85-$0.71-$1.17FY 202416-$5.61-$3.22-$4.35Q1 20252-$0.95-$0.76-$0.86Q2 20252-$0.96-$0.74-$0.85Q3 20252-$0.82$0.15-$0.34Q4 20252-$0.53$0.01-$0.26FY 20258-$3.26-$1.34-$2.30Q1 20261$0.33$0.33$0.33Q2 20261$0.09$0.09$0.09Q3 20261$0.64$0.64$0.64 Alnylam Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/20/2025(Estimated)------- 10/31/2024Q3 2024-$0.51-$0.87 -$0.36-$0.87$532.91M$500.90M 8/1/2024Q2 2024-$0.74-$0.13+$0.61-$0.13$447.22M$659.83M 5/2/2024Q1 2024-$0.75-$0.52+$0.23-$0.52$428.01M$494.33M 2/15/2024Q4 2023-$1.20-$1.10+$0.10-$1.10$439.38M$439.72M 11/2/2023Q3 2023-$1.61$1.15+$2.76$1.15$406.14M$750.53M 8/3/2023Q2 2023-$1.72-$2.21 -$0.49-$2.21$331.73M$318.75M I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman5/4/2023Q1 2023-$1.97-$1.40+$0.57-$1.40$312.53M$319.29M 2/23/2023Q4 2022-$2.13-$1.68+$0.45-$1.68$312.45M$335.04M Alnylam Pharmaceuticals Earnings - Frequently Asked Questions When is Alnylam Pharmaceuticals's earnings date? Alnylam Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates. Learn more on ALNY's earnings history. What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Thursday, October, 31st. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Did Alnylam Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) missed the analysts' consensus estimate of ($0.51) by $0.36 with a reported earnings per share (EPS) of ($0.87). Learn more on analysts' earnings estimate vs. ALNY's actual earnings. How can I listen to Alnylam Pharmaceuticals's earnings conference call? The conference call for Alnylam Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Alnylam Pharmaceuticals's conference call transcript? The conference call transcript for Alnylam Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Alnylam Pharmaceuticals's earnings report? Alnylam Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $1.83 billion. How much profit does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of -$440.24 million. ALNY has generated -$2.62 earnings per share over the last four quarters. What is Alnylam Pharmaceuticals's EPS forecast for next year? Alnylam Pharmaceuticals's earnings are expected to grow from ($2.22) per share to ($1.88) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies BeiGene Earnings Date Royalty Pharma Earnings Date Catalent Earnings Date Sarepta Therapeutics Earnings Date Elanco Animal Health Earnings Date Vertex Pharmaceuticals Earnings Date Gilead Sciences Earnings Date Regeneron Pharmaceuticals Earnings Date Biogen Earnings Date United Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report New post-election stock warning from Wall Street (Ad)If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...Not everything is as rosy as it seems on Wall Street. This page (NASDAQ:ALNY) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredReality Check: Are You Prepared for What's Next?Global shifts, like the alliance of BRICS nations pushing for economic independence from the U.S. dollar, and ...Allegiance Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
